stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Net margin
Fortrea Holdings Inc.'s net margin over the twelve months to 30 September 2026 was −2.58%, up 33.6 percentage points from fiscal 2025 (−36.2%). Over the past ten years it has ranged from −36.2% (fiscal 2025) to 6.56% (fiscal 2022) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −36.2% | (24.03) |
| FY2024 | −12.2% | (11.29) |
| FY2023 | −0.89% | (7.45) |
| FY2022 | 6.56% | 3.35 |
| FY2021 | 3.21% | 17.12 |
| FY2020 | −13.9% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2026 | 0.09% | 2.04 |
| Jun 2026 | −1.95% | 1.76 |
| Mar 2026 | −3.71% | 1.21 |
| Dec 2025 | −4.92% | (2.65) |
| 13 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | 18.1% |
| IMNM Immunome, Inc. compare | 0.00% |
| REPL Replimune Group, Inc. compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| FTRE Fortrea Holdings Inc. | −2.58% |
| SRPT Sarepta Therapeutics, Inc. compare | −5.86% |
| VIR Vir Biotechnology, Inc. compare | −61.0% |
| ZYME Zymeworks Inc. compare | −404.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.14% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue